BridgeBio Pharma ROA - Return on Assets 2018-2024 | BBIO

BridgeBio Pharma return on assets for the quarter ending June 30, 2024 was -63.71.

  • BridgeBio Pharma average return on assets for 2023 was -91.09, a 49.25% decline from 2022.
  • BridgeBio Pharma average return on assets for 2022 was -61.03, a 6.73% increase from 2021.
  • BridgeBio Pharma average return on assets for 2021 was -57.18, a 16.29% increase from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.

BridgeBio Pharma ROA - Return on Assets 2018-2024 | BBIO

  • BridgeBio Pharma average return on assets for 2023 was -91.09, a 49.25% decline from 2022.
  • BridgeBio Pharma average return on assets for 2022 was -61.03, a 6.73% increase from 2021.
  • BridgeBio Pharma average return on assets for 2021 was -57.18, a 16.29% increase from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$20.1B
Dr Reddy's Laboratories (RDY)$13.1B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.4B
Supernus Pharmaceuticals (SUPN)$1.8B
Taysha Gene Therapies (TSHA)$449M
Personalis (PSNL)$315M
Assembly Biosciences (ASMB)$117M
Acasti Pharma (ACST)$28M
Sol-Gel Technologies (SLGL)$20M
Evoke Pharma (EVOK)$4M
Teligent (TLGT)$0M